Cytotoxic activity of 2′,2′-difluorodeoxycytidine, 5-aza-2′-deoxycytidine and cytosine arabinoside in cells transduced with deoxycytidine kinase gene

Biochemical and Biophysical Research Communications

Volumn 293, Issue 5, 2002, Pages 1478-1484

  Beauséjour, Christian M ^a   Gagnon, Jacynthe ^a   Primeau, Mélanie ^a   Momparler, Richard L ^a  

^a UNIVERSITY OF MONTREAL   (Canada)

Author keywords

5 Aza 2 deoxycytidine; Cytidine deaminase; Cytosine arabinoside; Deoxycytidine kinase; Difluorodeoxycytidine; Thymidine kinase

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; CYTARABINE; CYTIDINE DEAMINASE; DEOXYCYTIDINE; DEOXYCYTIDINE KINASE; DNA; ENZYME; GEMCITABINE; NUCLEOSIDE; THYMIDINE KINASE;

ANIMAL CELL; ARTICLE; CELL ASSAY; CELL DEATH; CELL LINE; CELL STRAIN; CONTROLLED STUDY; CYTOTOXICITY; DEAMINATION; DNA SYNTHESIS; DRUG MECHANISM; DRUG SENSITIVITY; ENZYME ACTIVITY; ENZYME ASSAY; FIBROBLAST; GENETIC ANALYSIS; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; LUNG CARCINOMA; MITOCHONDRION; MOUSE; NONHUMAN; PHOSPHORYLATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; STRAIN DIFFERENCE; SUICIDE GENE; WILD TYPE;

ARA; MURINAE;

EID: 0036078423     PISSN: 0006291X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-291X(02)00413-8     Document Type: Article

References (34)

1. Phase I and pharmacologic study of sequences of gemcitabine and the multitargeted antifolate agent in patients with advanced solid tumors
2. Evaluation of the antitumor activity of gemcitabine (2′ 2′-difluoro-2′-deoxycytidine)
3. Combination chemotherapy with carboplatin, docetaxel, and gemcitabine in advanced non-small-cell lung cancer: A phase II study
4. Gemcitabine combined with continuous infusion 5-fluorouracil in advanced and symptomatic pancreatic cancer: A clinical benefit-oriented phase II study
5. Comparison of the cellular pharmacokinetics and toxicity of 2′,2′-difluorodeoxycytidine and 1-β-D-arabinofuranosylcytosine
6. Gemcitabine: Preclinical pharmacology and mechanisms of action
7. 2′,2′-Difluoro-deoxycytidine (gemcitabine) incorporation into RNA and DNA of tumour cell lines
8. Action of 2′,2′-difluorodeoxycytidine on DNA synthesis
9. Development and molecular characterization of a 2′,2′-difluorodeoxycytidine-resistant variant of the human ovarian carcinoma cell line A2780
10. Functional nucleoside transporters are required for gemcitabine influx and manifestation of toxicity in cancer cell lines
11. Overexpression of ribonucleotide reductase as a mechanism of resistance to 2,2-difluorodeoxycytidine in the human KB cancer cell line
12. Drug resistance to 5-aza-2′-deoxycytidine, 2′,2′-difluorodeoxycytidine, and cytosine arabinoside conferred by retroviral-mediated transfer of human cytidine deaminase cDNA into murine cells
13. Kinetic studies on 2′,2′-difluorodeoxycytidine (gemcitabine) with purified human deoxycytidine kinase and cytidine deaminase
14. Induction of in vivo resistance against gemcitabine (dFdC, 2′,2′-difluorodeoxycytidine)
15. Inhibition of protein kinase C activator-mediated induction of p21CIP1 and p27KIP1 by deoxycytidine analogs in human leukemia cells: Relationship to apoptosis and differentiation
16. Comparison of the induction of apoptosis in human leukemic cell lines by 2′,2′-difluorodeoxycytidine (gemcitabine) and cytosine arabinoside
17. Cloning of the cDNA and chromosome localization of the gene for human thymidine kinase 2
18. Human thymidine kinase 2: Molecular cloning and characterisation of the enzyme activity with antiviral and cytostatic nucleoside substrates
19. Incorporation of nucleoside analogs into nuclear or mitochondrial DNA is determined by the intracellular phosphorylation site
20. Transfection of wild-type deoxycytidine kinase (dck) cDNA into an AraC- and DAC-resistant rat leukemic cell line of clonal origin fully restores drug sensitivity
21. Viral vector transduction of the human deoxycytidine kinase cDNA sensitizes glioma cells to the cytotoxic effects of cytosine arabinoside in vitro and in vivo
22. Resistance to cytosine arabinoside by retrovirally mediated gene transfer of human cytidine deaminase into murine fibroblast and hematopoietic cells
23. A stable human-derived packaging cell line for production of high titer retrovirus/vesicular stomatitis virus G pseudotypes
24. Coexpression of cytidine deaminase and mutant dihydrofolate reductase by a bicistronic retroviral vector confers resistance to cytosine arabinoside and methotrexate
25. Selective assays for thymidine kinase 1 and 2 and deoxycytidine kinase and their activities in extracts from human cells and tissues
26. Pilot phase I-II study on 5-aza-2′-deoxycytidine (decitabine) in patients with metastatic lung cancer
27. Clinical trial on 5-aza-2′-deoxycytidine in patients with acute leukemia
28. Tumor uptake and elimination of 2′,2′-difluorodeoxycytidine (gemcitabine) after deoxycytidine kinase gene transfer: Correlation with in vivo tumor reponse
29. Disparity between gemcitabine incorporation and cytotoxicity in ovarian cancer cell lines treated with gemcitabine, multitargeted antifolate and thymidine
30. Bystander effects of nucleoside analogs phosphorylated in the cytosol or mitochondria
31. Retroviral transfer of deoxycytidine kinase into tumor cell lines enhances nucleoside toxicity
32. The modulation of the thymidine triphosphate pool of Chinese hamster cells by dCMP deaminase and UDP reductase: Thymidine auxotrophy induced by CTP IN dCMP deaminase-deficient line
33. Viral vectors for gene therapy: The art of turning infectious agents into vehicles of therapeutics
34. Relationship of deoxycytidine kinase and cytoplasmic 5′-nucleotidase to the chemotherapeutic efficacy of 2-chlorodeoxyadenosine